Clinical investigator associated with study at Alembic’s bioequivalence unit gets U.S. FDA warning letter
The U.S. Food and Drug Administration has issued a warning letter to a clinical investigator linked to a bioequivalence study at Alembic Pharmaceuticals. The regulatory action follows an inspection that identified deviations from standard clinical practice protocols.
The U.S. Food and Drug Administration (FDA) has formally issued a warning letter to a clinical investigator involved in a study conducted at Alembic Pharmaceuticals' bioequivalence unit. The letter highlights specific regulatory non-compliance issues discovered during a targeted inspection of the facility and its clinical trial records.
According to the regulatory documents, the investigator failed to ensure that the investigation was conducted according to the investigational plan. Such warnings typically indicate that the data generated during the study period may be subject to further scrutiny regarding its reliability for supporting drug applications.
Alembic Pharmaceuticals, an India-based generic drug manufacturer, utilizes these bioequivalence units to prove that its generic formulations perform the same way as brand-name counterparts. The FDA has requested a comprehensive response outlining corrective actions to prevent future recurrences of the cited violations. Source: The Economic Times.
